All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 24th April 2017, it was announced that the Idis Managed Access division of Clinigen Group and Onxeo have agreed to launch a Managed Access program for belinostat (marketed as BELEODAQ® in the U.S.) in Europe.
The program will allow physicians to request belinostat for specific patients for whom alternative treatment options are not currently available. On a named patient basis, this will allow access to belinostat ahead of a potential EU approval. The program will be available in 13 European countries: France, Spain, Germany, Belgium, Italy, The United Kingdom, Luxembourg, Austria, Denmark, Sweden, Norway, Finland, and The Netherlands.
Belinostat is a HDAC inhibitor used to treat R/R PTCL and in July 2014 received accelerated approval by the U.S. Food and Drug Administration (FDA) in this indication, primarily due to the large unmet need in this group of patients. Currently, belinostat does not hold any approvals in Europe.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox